Quality of life experience after neoadjuvant chemotherapy in HER2-positive breast cancer patients: a focus group study

• Conditions: breast cancer; mamma carcinoma; 10006291

• Registration Number: NL-OMON49288
• Lead Sponsor: Antoni van Leeuwenhoek Ziekenhuis

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 15 April 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 24

Inclusion Criteria

* Signed informed consent
* * 18 years
* Treated in the TRAIN-2 study for stage II or III HER2-positive breast cancer
at the NKI
* Willing and being able to fill in a questionnaire
* Willing to speak about and discuss different domains of HRQoL
* Proficient in Dutch

Exclusion Criteria

* Evidence of breast cancer recurrence / second primary cancer
* History of severe psychiatric illness or dementia

Study & Design

• Study Type: Observational non invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>health-related quality of life experience</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>not applicable</p><br>